Special Drug Use Investigation for Larotrectinib
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Larotrectinib (Primary)
- Indications CNS cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 13 Dec 2021 Status changed from not yet recruiting to recruiting.
- 24 Sep 2021 Planned initiation date changed from 30 Sep 2021 to 30 Oct 2021.
- 27 Jul 2021 Planned initiation date changed from 30 Jun 2021 to 30 Sep 2021.